Analysts expect AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report $-0.48 EPS on May, 1.They anticipate $0.58 EPS change or 54.72% from last quarter’s $-1.06 EPS. After having $0.10 EPS previously, AMAG Pharmaceuticals, Inc.’s analysts see -580.00% EPS growth. The stock decreased 2.52% or $0.5 during the last trading session, reaching $19.35. About 480,587 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has declined 16.25% since April 21, 2017 and is downtrending. It has underperformed by 27.80% the S&P500.
Cerus Corp (CERS) investors sentiment increased to 1.45 in 2017 Q4. It’s up 0.13, from 1.32 in 2017Q3. The ratio is better, as 45 institutional investors increased and started new equity positions, while 31 sold and trimmed holdings in Cerus Corp. The institutional investors in our database now hold: 58.96 million shares, up from 57.26 million shares in 2017Q3. Also, the number of institutional investors holding Cerus Corp in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 25 Increased: 31 New Position: 14.
Since January 1, 0001, it had 1 buy, and 5 sales for $597,723 activity.
Lesa Sroufe & Co holds 1.51% of its portfolio in Cerus Corporation for 540,752 shares. Elk Creek Partners Llc owns 6.55 million shares or 1.3% of their US portfolio. Moreover, Millrace Asset Group Inc. has 1.28% invested in the company for 395,202 shares. The New York-based Salzhauer Michael has invested 0.54% in the stock. First Midwest Bank Trust Division, a Illinois-based fund reported 784,416 shares.
Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on May, 2. They expect $-0.12 EPS, up 33.33% or $0.06 from last year’s $-0.18 per share. After $-0.10 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.
The stock decreased 3.00% or $0.17 during the last trading session, reaching $5.49. About 719,036 shares traded. Cerus Corporation (CERS) has risen 26.07% since April 21, 2017 and is uptrending. It has outperformed by 14.52% the S&P500.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $711.49 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.
Investors sentiment decreased to 0.9 in 2017 Q4. Its down 0.54, from 1.44 in 2017Q3. It turned negative, as 29 investors sold AMAG Pharmaceuticals, Inc. shares while 53 reduced holdings. 24 funds opened positions while 50 raised stakes. 37.72 million shares or 5.64% less from 39.98 million shares in 2017Q3 were reported. Tocqueville Asset Mngmt Limited Partnership reported 0.03% stake. Gotham Asset Mngmt Ltd Liability Corp has invested 0.01% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). 18,950 were reported by Stevens Mgmt Lp. Riverhead Capital Management Lc accumulated 4,383 shares or 0% of the stock. Thrivent Fin For Lutherans holds 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) or 21,932 shares. Goldman Sachs Grp Inc holds 231,655 shares. Invesco reported 145,481 shares or 0% of all its holdings. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Management Corp has invested 0.01% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Fmr Limited Co holds 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) or 1.64 million shares. Lsv Asset Mngmt owns 1.12M shares. Trexquant Investment L P reported 0.04% stake. Whittier Tru accumulated 2,292 shares or 0% of the stock. Massachusetts Fincl Ma has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Exane Derivatives accumulated 0.01% or 3,049 shares. Amundi Pioneer Asset Mngmt Inc stated it has 67,100 shares.
Among 14 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 3 have Buy rating, 1 Sell and 10 Hold. Therefore 21% are positive. AMAG Pharmaceuticals had 46 analyst reports since August 18, 2015 according to SRatingsIntel. On Tuesday, August 18 the stock rating was initiated by Jefferies with “Buy”. The company was maintained on Thursday, February 1 by Cantor Fitzgerald. The rating was maintained by Cantor Fitzgerald on Monday, July 24 with “Hold”. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Hold” rating by Jefferies on Monday, March 5. Needham downgraded AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Wednesday, January 11 to “Hold” rating. The rating was downgraded by Raymond James on Monday, January 9 to “Underperform”. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Hold” rating by Deutsche Bank on Thursday, September 3. Deutsche Bank maintained the shares of AMAG in report on Wednesday, November 4 with “Hold” rating. The firm has “Buy” rating given on Thursday, February 15 by Janney Capital. Jefferies maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Thursday, August 11 with “Buy” rating.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for women??s health, anemia management, and cancer supportive care in the United States. The company has market cap of $659.62 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.
Since February 23, 2018, it had 0 insider purchases, and 1 insider sale for $16,016 activity. On Friday, February 23 Vittiglio Joseph sold $16,016 worth of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) or 770 shares.